Dr Freitag obtained his medical degree from Kiel University, Germany in 1994. He started his career in the pharmaceutical industry at Roche in pharmacovigilance and medical affairs. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, finally as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to head up Vascular Medicine and moved on to become responsible for global clinical development across the portfolio. He joined Debiopharm International SA in 2016 to lead the clinical R&D function managing international drug development across Phase I to III. Recently, he joined Dynacure as Chief Medical Officer where he is responsible for medical and regulatory strategy, including clinical development of the lead compound in CNM.